Opaleye Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Opaleye Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-80,000	Closed	-$6.11M	–	53
2018 Q3	$6.11M	Hold	80,000	–	–	1.55%	23
2018 Q2	$6.15M	Hold	80,000	–	–	1.59%	24
2018 Q1	$4.08M	Sell	80,000 -10,000	-11%	-$504K	1.17%	24
2017 Q4	$4.17M	Buy	+90,000	New	+$4.41M	1.34%	23
2016 Q4	–	Sell	-35,000	Closed	-$2.48M	–	45
2016 Q3	$2.48M	Sell	35,000 -30,000	-46%	-$1.91M	1.3%	29
2016 Q2	$3.18M	Sell	65,000 -45,000	-41%	-$2.91M	2.12%	16
2016 Q1	$6.96M	Hold	110,000	–	–	4.34%	3
2015 Q4	$12.3M	Hold	110,000	–	–	5.16%	1
2015 Q3	$10.6M	Hold	110,000	–	–	5.21%	2
2015 Q2	$11.3M	Hold	110,000	–	–	4.48%	6
2015 Q1	$6.83M	Buy	110,000 +3,800	+4%	+$211K	3.17%	11
2014 Q4	$4.66M	Buy	106,200 +21,200	+25%	+$971K	2.35%	13
2014 Q3	$4.81M	Buy	85,000 +40,000	+89%	+$2.01M	3.75%	9
2014 Q2	$2.02M	Buy	+45,000	New	+$1.85M	1.74%	16

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Opaleye Management's RARE Position: Q4 2018 in Review

Opaleye Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 80,000 shares — an estimated $6.11M sold.

Opaleye Management first reported a position in RARE in Q2 2014 and held it in 14 quarters. The position peaked at $12.3M in Q4 2015. 165 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

Opaleye Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Opaleye Management sold 80,000 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $6.11M.
Opaleye Management first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and held it in 14 quarters.
Opaleye Management's Ultragenyx Pharmaceutical position peaked at $12.3M in Q4 2015.
165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.